4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Autophagy-associated circRNA circATG7 facilitates autophagy and promotes pancreatic cancer progression

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dysregulation of autophagy and circular RNAs (circRNAs) are involved in the pancreatic cancer (PC) progression. However, the regulatory network between circRNAs, autophagy, and PC progression remains unknown. Herein, we demonstrated that autophagy-associated circRNA circ-autophagy related 7 (circATG7) was elevated in PC tissues compared to adjacent tissues, and in PC cells treated with EBSS and hypoxia. circATG7 expression was positively associated with tumor diameter and lymph node invasion in patients with PC. circATG7 overexpression promoted PC cell proliferation, mobility, and autophagy in vitro, while circATG7 knockdown induced the opposite effects. ATG7 inhibition attenuated the effects of circATG7 on the biological functions of PC cells. CircATG7 is located in the cell cytoplasm and nucleus. Cytoplasmic circATG7 sponged miR-766-5p and decreased its expression, and increased the expression of ATG7, a target gene of miR-766-5p. Nuclear circATG7 acted as a scaffold to increase the interaction between the human antigen R protein and ATG7 mRNA and enhanced ATG mRNA stability. Furthermore, we demonstrated that circATG7 regulates PC cell proliferation and metastasis in vivo via ATG7-dependent autophagy. In conclusion, our results demonstrated that circATG7 accelerates PC progression via miR-766-5p/ATG7 and that HUR/ATG7 depends on autophagic flux. Thus, circATG7 may be a potential therapeutic target for PC.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer statistics, 2020

          Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2016) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2017) were collected by the National Center for Health Statistics. In 2020, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States. The cancer death rate rose until 1991, then fell continuously through 2017, resulting in an overall decline of 29% that translates into an estimated 2.9 million fewer cancer deaths than would have occurred if peak rates had persisted. This progress is driven by long-term declines in death rates for the 4 leading cancers (lung, colorectal, breast, prostate); however, over the past decade (2008-2017), reductions slowed for female breast and colorectal cancers, and halted for prostate cancer. In contrast, declines accelerated for lung cancer, from 3% annually during 2008 through 2013 to 5% during 2013 through 2017 in men and from 2% to almost 4% in women, spurring the largest ever single-year drop in overall cancer mortality of 2.2% from 2016 to 2017. Yet lung cancer still caused more deaths in 2017 than breast, prostate, colorectal, and brain cancers combined. Recent mortality declines were also dramatic for melanoma of the skin in the wake of US Food and Drug Administration approval of new therapies for metastatic disease, escalating to 7% annually during 2013 through 2017 from 1% during 2006 through 2010 in men and women aged 50 to 64 years and from 2% to 3% in those aged 20 to 49 years; annual declines of 5% to 6% in individuals aged 65 years and older are particularly striking because rates in this age group were increasing prior to 2013. It is also notable that long-term rapid increases in liver cancer mortality have attenuated in women and stabilized in men. In summary, slowing momentum for some cancers amenable to early detection is juxtaposed with notable gains for other common cancers.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Regulation of circRNA biogenesis.

            Unlike linear RNAs terminated with 5' caps and 3' tails, circular RNAs are characterized by covalently closed loop structures with neither 5' to 3' polarity nor polyadenylated tail. This intrinsic characteristic has led to the general under-estimation of the existence of circular RNAs in previous polyadenylated transcriptome analyses. With the advent of specific biochemical and computational approaches, a large number of circular RNAs from back-spliced exons (circRNAs) have been identified in various cell lines and across different species. Recent studies have uncovered that back-splicing requires canonical spliceosomal machinery and can be facilitated by both complementary sequences and specific protein factors. In this review, we highlight our current understanding of the regulation of circRNA biogenesis, including both the competition between splicing and back-splicing and the previously under-appreciated alternative circularization.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Autophagy and autophagy-related proteins in cancer

              Autophagy, as a type II programmed cell death, plays crucial roles with autophagy-related (ATG) proteins in cancer. Up to now, the dual role of autophagy both in cancer progression and inhibition remains controversial, in which the numerous ATG proteins and their core complexes including ULK1/2 kinase core complex, autophagy-specific class III PI3K complex, ATG9A trafficking system, ATG12 and LC3 ubiquitin-like conjugation systems, give multiple activities of autophagy pathway and are involved in autophagy initiation, nucleation, elongation, maturation, fusion and degradation. Autophagy plays a dynamic tumor-suppressive or tumor-promoting role in different contexts and stages of cancer development. In the early tumorigenesis, autophagy, as a survival pathway and quality-control mechanism, prevents tumor initiation and suppresses cancer progression. Once the tumors progress to late stage and are established and subjected to the environmental stresses, autophagy, as a dynamic degradation and recycling system, contributes to the survival and growth of the established tumors and promotes aggressiveness of the cancers by facilitating metastasis. This indicates that regulation of autophagy can be used as effective interventional strategies for cancer therapy.
                Bookmark

                Author and article information

                Contributors
                1006074061@qq.com
                lixw1966@163.com
                Journal
                Cell Death Dis
                Cell Death Dis
                Cell Death & Disease
                Nature Publishing Group UK (London )
                2041-4889
                14 March 2022
                14 March 2022
                March 2022
                : 13
                : 3
                : 233
                Affiliations
                [1 ]GRID grid.263488.3, ISNI 0000 0001 0472 9649, Department of Hepatobiliary Surgery, , Shenzhen Key Laboratory, Shenzhen University General Hospital, ; Shenzhen, Guangdong 518055 China
                [2 ]GRID grid.508211.f, ISNI 0000 0004 6004 3854, Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Health Science Center, ; Shenzhen, 518060 China
                [3 ]GRID grid.263488.3, ISNI 0000 0001 0472 9649, Guangdong Provincial Key Laboratory of Regional Immunity and Diseases & Carson International Cancer Center, Shenzhen University, ; Shenzhen, Guangdong 518055 China
                [4 ]GRID grid.263488.3, ISNI 0000 0001 0472 9649, Shenzhen University Clinical Medical Academy Center, Shenzhen University, ; Shenzhen, Guangdong 518055 China
                [5 ]GRID grid.413458.f, ISNI 0000 0000 9330 9891, Guizhou Medical University, ; Guiyang, China
                [6 ]GRID grid.452244.1, Department of Hepatic-Biliary-Pancreatic Surgery, , The Affiliated Hospital of Guizhou Medical University, ; Guiyang, 550000 Guizhou China
                [7 ]GRID grid.413458.f, ISNI 0000 0000 9330 9891, School of Basic Medicine, Guizhou Medical University, ; Guiyang, 550025 Guizhou China
                Author information
                http://orcid.org/0000-0002-1434-2170
                http://orcid.org/0000-0002-0070-5954
                http://orcid.org/0000-0001-9547-9074
                http://orcid.org/0000-0002-8221-7064
                Article
                4677
                10.1038/s41419-022-04677-0
                8921308
                35288538
                a3a76f81-f575-476e-8253-572a8685efb0
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 6 October 2021
                : 5 February 2022
                : 18 February 2022
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100001809, National Natural Science Foundation of China (National Science Foundation of China);
                Award ID: 81960433
                Award ID: 81430063
                Award Recipient :
                Funded by: Laboratory and Talent Project of Guizhou Cooperational Science Foundation [2018]5779-34
                Funded by: grants from Education Department of Guizhou Province Project [No. YJSCXJH (2020) 147]
                Funded by: Guangdong Provincial Science and Technology Program [grant numbers 2019B030301009], Natural Science Foundation of Guangdong Province of China [grant numbers 2021A1515012161], Guangdong Province Regional Joint Fund-Key Projects [grant numbers 2020B1515120096], Sanming Project of Medicine in Shenzhen [grant numbers SZSM202003009], Shenzhen Key Laboratory Foundation [grant numbers ZDSYS20200811143757022] and Shenzhen International Cooperative Research Project [grant numbers GJHZ20200731095210030].
                Categories
                Article
                Custom metadata
                © The Author(s) 2022

                Cell biology
                pancreatic cancer
                Cell biology
                pancreatic cancer

                Comments

                Comment on this article